Cathie Wood Dumps the Last of Teradyne From Her Flagship Fund
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) sold its last Teradyne (NASDAQ:TER | TER Price Prediction) shares on Wednesday, November 11, 2026. ARK’s daily trade file put the sale at about $110,300 and marked it as 100% of the fund’s position.
The bulk of the selling happened a day earlier. On November 10, ARK’s trade file showed ARKK selling about $1.4 million of Teradyne, or 95.09% of its stake.
The stock went the other way. Teradyne rose 8.30% to $265.78 on November 11, the same day Jefferies started coverage at Buy with a $284 target. After hours, it slid 2.75% to $258.48. ARK did not say why it sold.
What ARK’s Trade Files Show
ARKK’s November 11 holdings file listed 415 shares worth $101,841, and the final trade cleared them out.
Nothing else was disclosed. Neither Wood nor ARK posted an explanation on X or anywhere else, so any reason, including timing the rally, would be a guess.
ARK still owns Teradyne. The ARK Autonomous Technology and Robotics ETF (NYSEARCA:ARKQ) held 231,809 shares worth $56.9 million, a 3.32% weight, in its November 11 filing. At the close, that stake came to about $61.6 million.
Teradyne Barely Registers the ARKK Sale
Both ARKK sales are tiny next to a $41.49 billion market cap. They tell you about one fund’s holdings and nothing about the business.
Teradyne makes automated test equipment, the machines that check chips before they ship, and it also has a robotics unit. AI processors and high-bandwidth memory need more testing, and test’s share of chip capital spending rose from 6.4% in 2025 to 8.1% for the first eight months of 2026.
Third-quarter revenue exceeded $1.3 billion, up 70%, and non-GAAP EPS of $2.29 beat expectations. Management said, “AI-driven revenue represents more than 60% of total revenue.”
Reality Check: Two ARK Funds, Two Mandates
ARKK goes after broad disruptive innovation, and a dividend-paying equipment maker worth tens of billions no longer looks like an early-stage holding. ARKQ’s automation focus fits Teradyne’s robotics arm, which reached profitability in the third quarter.
ARKK’s money moved elsewhere on November 11. ARKK and ARKQ added about $3.1 million of Kratos Defense (NASDAQ:KTOS), and ARK’s genomics fund bought about $7.5 million of Prime Medicine (NASDAQ:PRME). Other ARK funds bought space and air-mobility names.
Teradyne closed at a record $483.84 on June 30, then fell to $212.74 by November 5, including a 15.24% drop that day, and it remains down 30.76% over the past month.
Chip-equipment spending runs in cycles, and Teradyne’s biggest new computing programs depend on a handful of hyperscaler and GPU customers whose ramps are expected in 2027.
What Could Move TER Stock After ARK’s Exit
The ARKK exit looks like portfolio housekeeping within one fund, and ARK’s much larger ARKQ stake remains in place.
Management guided fourth-quarter revenue of $1,250M to $1,350M and expects 2027 to be another year of healthy growth. Since the November 5 low, the stock has rallied about 25%, but it still trades far below its June record.
The cost is volatility. A 12.73% gain on November 9 shows how far this stock can move in a single session.
You can check this view against two things. First, see whether ARKQ’s daily file starts cutting its 231,809 shares. Second, see whether Teradyne holds above its $212.74 November 5 close going into the fourth-quarter earnings call, where management plans to provide an updated model. A close below that level would mean the market doubts AI test demand more than the results do.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
